📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
502 analysed today
FollowTelegram
502
Today
149,903
All-time analysed
42,967
Positive
6,669
Negative
91,560
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
251 announcements match the current filters (relevance ≥ 5).
Shalby Q4 FY26: PAT Reaches ₹18.5 Cr; MedTech Segment Turns EBITDA Positive
Shalby Limited reported a strong Q4 FY26 with consolidated revenue growing 9.4% YoY to ₹295.5 crores and EBITDA rising 43.1% to ₹37.4 crores. The company achieved a significant turnaround in profitability, posting a PAT of ₹18.5 crores compared to a loss of ₹12.2 crores in the previous year, aided by a transition to a new tax regime. The MedTech (implant) business showed robust growth, with annual revenue crossing ₹135 crores and turning EBITDA positive at ₹6.7 crores for the full year. Despite geopolitical headwinds affecting the Gurugram unit's international patient flow, overall operational metrics like ARPOB and occupancy remained stable.
Key Highlights
Consolidated EBITDA grew by 43.1% YoY to ₹37.4 crores in Q4 FY26, with margins expanding to 12.7%.
Shalby MedTech revenue increased by 46% in FY26 to ₹135 crores, achieving a full-year positive EBITDA of ₹6.7 crores.
Standalone ARPOB improved by 2.7% to ₹42,689, while group-level occupancy stood at 48% (50% excluding the Gurugram unit).
The company successfully completed 70 transplants, including 51 kidney and 19 liver transplants, during FY26.
Maintained a healthy balance sheet with a gearing ratio of 0.44x and net debt of ₹446.2 crores.
👀 What to Watch
Investors should focus on the successful turnaround of the MedTech segment and the recurring tax benefits which are expected to sustain higher PAT margins. Monitor the recovery of international patient volumes at the Gurugram facility as geopolitical tensions ease.
Vaishali Pharma Approves Audited Q4 and FY26 Financial Results
The Board of Directors of Vaishali Pharma Limited met on May 30, 2026, to approve the audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The meeting was held late in the evening, concluding at 10:50 P.M. This announcement confirms the completion of the annual audit process in compliance with SEBI regulations. While specific financial figures were not detailed in the cover letter, the approval marks the formal release of the company's performance data for the 2025-26 fiscal year.
Key Highlights
Board approved Audited Standalone and Consolidated Financial Results for the year ended March 31, 2026.
The meeting was conducted on May 30, 2026, starting at 10:00 P.M. and ending at 10:50 P.M.
The submission includes the Audit Report for both the fourth quarter and the full financial year.
Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.
👀 What to Watch
Investors should review the detailed financial tables in the attached Annexure I to assess revenue growth and margin stability. Compare the full-year FY26 performance against FY25 to determine the company's growth trajectory.
Shalimar Paints CFO Sachin Naik Resigns Effective May 30, 2026
Mr. Sachin Naik has resigned from his position as the Chief Financial Officer (CFO) and Key Managerial Personnel of Shalimar Paints Limited. The resignation is effective from the close of business hours on May 30, 2026. The company stated the reason for his departure is to pursue better career opportunities and professional growth prospects. No immediate successor was announced in the filing.
Key Highlights
Mr. Sachin Naik resigned as Chief Financial Officer (CFO) effective May 30, 2026.
The resignation is categorized as a change in Key Managerial Personnel (KMP) under SEBI regulations.
The stated reason for resignation is better career opportunities and professional growth.
The disclosure was filed in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
👀 What to Watch
Investors should monitor the company's upcoming announcements for the appointment of a new CFO to ensure leadership continuity and stability in financial management.
Shalimar Paints CFO Sachin Naik Resigns Effective May 30, 2026
Mr. Sachin Naik has resigned from his position as the Chief Financial Officer (CFO) and Key Managerial Personnel of Shalimar Paints Limited. The resignation is effective from the close of business hours on May 30, 2026. The company cited better career opportunities and professional growth as the reasons for his departure. Investors should watch for the announcement of a successor to ensure a smooth transition in the finance department.
Key Highlights
Sachin Naik resigned as CFO and Key Managerial Personnel effective May 30, 2026.
The resignation is attributed to better career opportunities and professional growth prospects.
The disclosure was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
The company has not yet named a replacement for the outgoing CFO.
👀 What to Watch
Monitor the company's upcoming announcements for the appointment of a new CFO to ensure leadership stability. No immediate action is required as the resignation appears to be a routine career move.
Shah Alloys FY26 Results: Massive Exceptional Gains of ₹9,000+ Lakhs Amidst Plant Closure
Shah Alloys Limited reported its FY26 results, heavily influenced by one-time exceptional gains from asset liquidations and debt settlements. While the company recorded significant gains including ₹5,347.68 lakhs from plant sales and ₹1,398.41 lakhs from SAL Steel disinvestment, its core Iron and Steel plant has been shut down since August 2025. Auditors have issued a 'Material Uncertainty Related to Going Concern' warning due to the cessation of operations and persistent losses. The company also settled HDFC Bank dues of ₹2,523.77 lakhs for a reduced payment of ₹1,800 lakhs.
Key Highlights
Recognized an exceptional gain of ₹5,347.68 lakhs from the sale of plant, machinery, and technical know-how.
Settled HDFC Bank liabilities of ₹2,523.77 lakhs for ₹1,800 lakhs, resulting in a ₹723.77 lakhs waiver.
Auditors raised 'Material Uncertainty' regarding the company's ability to continue as a going concern following the August 2025 plant shutdown.
Booked a profit of ₹1,691.53 lakhs from the sale of its 16-inch Rolling Mill Plant for ₹1,700 lakhs.
Realized a gain of ₹1,398.41 lakhs through the disinvestment of shares in associate company SAL Steel Limited.
👀 What to Watch
Investors should remain highly cautious as the reported profits are driven by asset sales rather than core business operations, which have effectively ceased. The auditor's 'going concern' warning is a major red flag indicating the company's future viability is at risk.
Shalimar Paints Reports First Positive EBITDA Since Acquisition in FY26 Results
Shalimar Paints has achieved a significant operational milestone by reporting positive EBITDA for the full year FY 2025-26, the first since its acquisition by Hella Infra Market Limited. The company successfully implemented cost rationalization measures, specifically reducing employee and manufacturing expenses to improve operating leverage. A strategic shift towards premiumization, particularly in high-margin emulsion products, has enhanced the overall margin profile. Despite industry-wide pricing pressures and volatile demand, the management indicates a successful business turnaround and a strengthened foundation for sustainable growth.
Key Highlights
Delivered positive EBITDA for the first time since the majority stake acquisition by Hella Infra Market Limited.
Executed focused cost rationalization leading to significant reductions in employee, manufacturing, and operating expenses.
Improved product mix through premiumization and increased saliency of high-margin emulsion products.
Statutory auditors Walker Chandiok & Co., LLP issued an unmodified opinion on the audited financial results.
Strengthened business fundamentals and operational efficiencies despite persistent sector-wide headwinds.
👀 What to Watch
Investors should view the positive EBITDA as a critical turnaround signal and monitor if this leads to consistent net profitability. Watch for the company's ability to maintain market share against larger competitors while sustaining these improved margins.
Halder Venture Approves FY26 Results & Proposes ₹1,000 Cr Borrowing Limit Increase
Halder Venture Limited has approved its audited financial results for the fiscal year ended March 31, 2026. A major highlight is the board's proposal to increase the company's borrowing limits and investment/loan limits to ₹1,000 crores each, pending shareholder approval. The company is also undergoing a statutory auditor transition, proposing P. Somani & Co. for a five-year term as the current auditor's tenure concludes. These structural and financial limit changes suggest the company is positioning itself for significant capital deployment or expansion.
Key Highlights
Approved standalone and consolidated audited financial results for the quarter and year ended March 31, 2026.
Proposed a significant increase in borrowing limits up to ₹1,000 crores under Section 180(1)(c).
Proposed increasing limits for providing loans, guarantees, and investments up to ₹1,000 crores under Section 186.
Recommended the appointment of M/s P. Somani & Co. as Statutory Auditors for a 5-year term starting from the 44th AGM.
Reappointed J Kumar Jain & Associates as Internal Auditors and J Pal & Co as Cost Auditors for FY 2026-27.
👀 What to Watch
Investors should closely monitor the specific reasons for the massive hike in borrowing limits to ₹1,000 crores, as this may precede a major acquisition or expansion phase. It is also essential to review the full audited financial report to evaluate the company's current debt-to-equity ratio before these new limits are utilized.
Halder Venture Approves FY26 Results; Proposes ₹1,000 Cr Borrowing & Investment Limit
Halder Venture Limited has approved its FY26 audited financial results and proposed a significant increase in its financial flexibility. The board has cleared an increase in borrowing limits to ₹1,000 Crores and a similar limit for loans and investments, pending shareholder approval. Additionally, the company is appointing P. Somani & Co. as the new Statutory Auditor for a five-year term following the completion of the previous auditor's tenure. These structural changes indicate a potential shift towards aggressive expansion or capital deployment in the near future.
Key Highlights
Approved standalone and consolidated audited financial results for the year ended March 31, 2026.
Proposed a substantial increase in borrowing limits up to ₹1,000 Crores under Section 180(1)(c).
Approved a limit of ₹1,000 Crores for providing loans, guarantees, and making investments under Section 186.
Recommended P. Somani & Co. as Statutory Auditor for a 5-year tenure starting from the 44th AGM.
Approved the reappointment of Internal and Cost Auditors for the Financial Year 2026-2027.
👀 What to Watch
Investors should monitor the specific utilization plans for the ₹1,000 Crore borrowing limit, as this suggests significant upcoming CAPEX or M&A activity. Review the full FY26 financial statements to assess the company's current leverage and profitability before the debt expansion.
Halder Venture FY26 Results: Proposes ₹1,000 Cr Borrowing Limit & New Auditor
Halder Venture Limited has approved its audited financial results for FY26 and is seeking shareholder approval for a massive expansion in financial capacity, raising borrowing and investment limits to ₹1,000 crores each. The company is appointing P. Somani & Co. as the new statutory auditor for a five-year term following the tenure completion of the previous auditor. An audit note highlighted a regulatory breach where subsidiaries hold 6.61% of the company's own shares, though a disposal process has initiated. This indicates a period of significant corporate restructuring and potential capital-intensive expansion.
Key Highlights
Proposed increase in borrowing limits to ₹1,000 crores to support future operations
Proposed investment and loan limits raised to ₹1,000 crores under Section 186 of the Companies Act
Appointment of P. Somani & Co. as Statutory Auditor for a 5-year term (2026-2031)
Audit report flagged 8,22,654 shares (6.61%) held by subsidiaries in violation of Section 19
Approved commission payment to Non-Executive Director Mrs. Poulomi Halder subject to shareholder approval
👀 What to Watch
Investors should monitor the specific deployment plan for the newly proposed ₹1,000 crore capital limit and track the progress of the subsidiary share disposal to ensure regulatory compliance.
Simbhaoli Sugars Appoints Auditors and Approves FY26 Financial Results Amid CIRP
Simbhaoli Sugars, currently under the Corporate Insolvency Resolution Process (CIRP), has appointed new Cost and Secretarial Auditors to maintain statutory compliance. The Interim Resolution Professional (IRP) has taken on record a backlog of financial results, including consolidated results for three quarters of 2025 and audited standalone results for the full year ended March 31, 2026. Although the CIRP process is currently stayed by the NCLAT pending settlement discussions, the IRP remains in control of management. These actions are necessary steps to keep the company's regulatory filings current during its legal restructuring.
Key Highlights
M/s Amit Gupta & Associates appointed as Secretarial Auditor for a 5-year term (FY 2025-26 to 2029-30).
M/s Cheena & Associates appointed as Cost Auditor for Sugar and Distillery units for FY 2025-26.
Audited standalone financial results for the year ended March 31, 2026, were approved and taken on record.
Company has been under CIRP since July 11, 2024, with the Board of Directors currently suspended.
NCLAT has reserved judgment on the CIRP stay as of May 13, 2026, following settlement discussions with creditors.
👀 What to Watch
Investors should remain highly cautious as the company is in insolvency; the key trigger to watch is the NCLAT's final judgment on the CIRP stay and the outcome of creditor settlements.
Simbhaoli Sugars Appoints Auditors and Clears Multi-Quarter Financial Results Amid CIRP
Simbhaoli Sugars, currently under the Corporate Insolvency Resolution Process (CIRP), has appointed M/s Cheena & Associates as Cost Auditors and M/s Amit Gupta & Associates as Secretarial Auditors for FY 2025-26. The Interim Resolution Professional (IRP) has also taken on record the pending financial results for the quarters ended June, September, and December 2025, as well as the audited standalone results for the full year ended March 31, 2026. Crucially, the statutory auditors issued an 'Adverse Opinion' on the consolidated results for the quarter ended June 30, 2025, reflecting severe financial instability. The company's board remains suspended, and management is controlled by the IRP under the Insolvency and Bankruptcy Code.
Key Highlights
Appointed M/s Cheena & Associates as Cost Auditor for Sugar and Distillery units for FY 2025-26.
Appointed M/s Amit Gupta & Associates as Secretarial Auditor for a five-year term through FY 2029-30.
Cleared a backlog of financial results including Q1, Q2, Q3 of FY 2025-26 and full-year audited results for FY 2025-26.
Statutory auditors issued an Adverse Opinion on the Q1 FY 2025-26 consolidated financial results.
The company remains under CIRP since July 11, 2024, with operations currently stayed by NCLAT pending settlement discussions.
👀 What to Watch
Investors should exercise extreme caution as the company is in active insolvency proceedings and auditors have issued an adverse opinion on financial statements. The stock is highly speculative and subject to the outcome of the NCLAT judgment and the resolution process.
Simbhaoli Sugars Approves FY26 Audited Results Amid CIRP and Adverse Auditor Opinion
Simbhaoli Sugars has approved its standalone audited financial results for the year ended March 31, 2026, along with a backlog of unaudited consolidated results for Q1, Q2, and Q3 of FY26. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP), although the process is stayed by the NCLAT pending a final judgment. Crucially, the statutory auditors have issued an 'Adverse Opinion' on the consolidated results for the quarter ended June 30, 2025, indicating significant reporting concerns. New Cost and Secretarial Auditors have been appointed to maintain statutory compliance during the insolvency period.
Key Highlights
Approved Audited Standalone Financial Results for the full year ended March 31, 2026.
Statutory auditors issued an 'Adverse Opinion' on the consolidated financial results for the quarter ended June 30, 2025.
Cleared reporting backlog by taking on record unaudited consolidated results for Q1, Q2, and Q3 of FY 2025-26.
Appointed M/s Amit Gupta & Associates as Secretarial Auditors for a five-year term through FY 2029-30.
The company remains under CIRP since July 11, 2024, with the NCLAT judgment on the process currently reserved as of May 13, 2026.
👀 What to Watch
Investors should remain highly cautious as the 'Adverse Opinion' from auditors and the ongoing insolvency proceedings suggest high risk. The stock is speculative until the NCLAT delivers its final judgment and the financial discrepancies are addressed.
Simbhaoli Sugars Reports FY26 Results Under CIRP; Auditors Issue Adverse Opinion
Simbhaoli Sugars Limited, currently undergoing the Corporate Insolvency Resolution Process (CIRP), has released its financial results for the first three quarters of FY2025-26 and audited standalone results for the full year ended March 31, 2026. The statutory auditors, B.K. Kapur & Company, have issued an 'Adverse Opinion' on the consolidated results for the quarter ended June 30, 2025. The company's operations are being managed by an Interim Resolution Professional (IRP) as the NCLAT has reserved its judgment regarding the stay on the insolvency process.
Key Highlights
Consolidated Unaudited Financial Results for Q1, Q2, and Q3 of FY2025-26 were approved and taken on record by the IRP.
Auditors issued an Adverse Opinion on the Consolidated Financial Results for the quarter ended June 30, 2025.
Standalone Audited Financial Results for the full year ended March 31, 2026, were approved by the CFO and IRP.
M/s Cheena & Associates appointed as Cost Auditor for FY2025-26; M/s Amit Gupta & Associates appointed as Secretarial Auditor for five years.
The company remains under CIRP since July 11, 2024, with the NCLAT having reserved judgment on the matter on May 13, 2026.
👀 What to Watch
Investors should remain highly cautious as the company is in insolvency proceedings and has received an adverse auditor's opinion on its financial reporting. The stock remains a high-risk play pending the final NCLAT judgment and the outcome of the debt settlement discussions.
Simbhaoli Sugars Approves FY26 Results and Multiple Quarterly Filings Amid Ongoing CIRP
Simbhaoli Sugars, currently under the Corporate Insolvency Resolution Process (CIRP), has approved its audited standalone results for FY26 and unaudited consolidated results for the first three quarters of FY26. The company is operating under an Interim Resolution Professional (IRP) as the board remains suspended, though the CIRP process is currently stayed by the NCLAT pending settlement discussions. Notably, the statutory auditors have issued an adverse opinion on the consolidated results for the quarter ended June 30, 2025, signaling significant reporting concerns.
Key Highlights
Approved audited standalone financial results for the full year ended March 31, 2026
Cleared reporting backlog for unaudited consolidated results for quarters ended June, September, and December 2025
Statutory auditors issued an Adverse Opinion on the consolidated financial results for the quarter ended June 30, 2025
Appointed M/s Cheena & Associates as Cost Auditor and M/s Amit Gupta & Associates as Secretarial Auditor for FY 2025-26
CIRP process remains stayed by NCLAT as of May 2026, with a final judgment reserved on May 13, 2026
👀 What to Watch
Investors should exercise extreme caution as the company remains in insolvency proceedings and has received an adverse auditor opinion. The primary focus should be on the upcoming NCLAT judgment which will determine the company's legal and operational future.
Simbhaoli Sugars Reports Delayed Financials Amid CIRP; Auditors Issue Adverse Opinion
Simbhaoli Sugars, currently under the Corporate Insolvency Resolution Process (CIRP), has released multiple quarters of delayed financial results and appointed new auditors. The company's board remains suspended, with the Interim Resolution Professional (IRP) managing operations under a stay order from the NCLAT. Notably, the statutory auditors have issued an adverse opinion on the consolidated results for the quarter ended June 30, 2025. This indicates significant concerns regarding the company's financial reporting and its ability to continue as a going concern amidst ongoing legal and insolvency proceedings.
Key Highlights
Company is undergoing CIRP since July 11, 2024, with board powers suspended and managed by an IRP.
Auditors issued an 'Adverse Opinion' on the consolidated financial results for the quarter ended June 30, 2025.
Delayed financial results for Q1, Q2, Q3 of FY2025 and Audited Standalone results for FY2026 were taken on record.
M/s Amit Gupta & Associates appointed as Secretarial Auditor for a 5-year term starting FY 2025-26.
NCLAT has reserved judgment on the CIRP matter as of May 13, 2026, following settlement discussions among creditors.
👀 What to Watch
Investors should exercise extreme caution as the company is in insolvency proceedings and has received an adverse auditor opinion. The stock remains highly speculative until the NCLAT judgment is pronounced and a clear resolution plan or settlement is finalized.
Haleos Labs Recommends Rs 1.50 Dividend; FY26 Net Profit Declines 16.8% YoY
Haleos Labs Limited has recommended a final dividend of Rs 1.50 (15%) per equity share for FY2025-26. The company's annual standalone revenue declined to Rs 300.99 crore from Rs 333.37 crore in the previous year. Net profit for the full year also saw a contraction, falling to Rs 17.78 crore from Rs 21.37 crore. Alongside results, the company announced the resignation of an independent director and the reappointment of a Whole-time Director for five years.
Key Highlights
Recommended a final dividend of Rs 1.50 per equity share of Rs 10 face value.
Annual standalone revenue decreased by 9.7% YoY to Rs 30,098.96 Lakhs.
Standalone Net Profit for FY26 fell to Rs 1,777.68 Lakhs compared to Rs 2,137.08 Lakhs in FY25.
Q4 FY26 revenue dropped significantly to Rs 6,338.42 Lakhs from Rs 8,542.78 Lakhs in the year-ago quarter.
Earnings Per Share (EPS) for the full year decreased to Rs 58.80 from Rs 70.69.
👀 What to Watch
Investors should exercise caution as the dividend payout comes amid declining revenue and profitability. Monitor the company's ability to arrest the top-line slide and the impact of the upcoming statutory auditor change.
Haleos Labs FY26 Revenue Drops 9.7% to ₹301 Cr; Recommends ₹1.50 Dividend
Haleos Labs reported a decline in its financial performance for the fiscal year ended March 31, 2026, with annual revenue dropping to ₹300.99 crore from ₹333.37 crore in the previous year. Net profit for the full year also saw a contraction, falling to ₹17.78 crore compared to ₹21.37 crore in FY25. Despite the lower earnings, the board has recommended a dividend of ₹1.50 per equity share (15% of face value). The company also announced the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for five years.
Key Highlights
Annual Revenue from Operations decreased by 9.7% YoY to ₹30,098.96 Lakhs in FY26.
Net Profit for FY26 fell by 16.8% to ₹1,777.68 Lakhs from ₹2,137.08 Lakhs in FY25.
Board recommended a dividend of ₹1.50 per equity share (15%) for the financial year 2025-26.
Q4 FY26 Revenue stood at ₹6,338.42 Lakhs, a significant drop from ₹8,542.78 Lakhs in the year-ago quarter.
Mrs. Sudeepthi Gopineedi reappointed as Whole-time Director for 5 years effective Sept 2, 2026.
👀 What to Watch
The decline in both top-line and bottom-line performance is concerning; investors should wait for management commentary on margin pressures. The dividend provides a small yield, but the focus should remain on the company's ability to reverse the revenue slide.
Shalimar Paints Reports First Positive EBITDA Since Acquisition in FY26 Results
Shalimar Paints Limited has achieved a significant operational milestone by delivering positive EBITDA for the financial year ended March 31, 2026, marking its first such performance since Hella Infra Market Limited acquired a majority stake. The company successfully executed cost rationalization initiatives, resulting in lower employee and manufacturing expenses. A strategic shift toward a premium product mix, specifically high-margin emulsions, has enhanced the overall margin profile. Despite industry-wide pricing pressures, the company reports a successful business turnaround and improved operational leverage.
Key Highlights
Delivered positive EBITDA for the first time since the acquisition by Hella Infra Market Limited.
Executed significant cost reductions in employee costs, manufacturing, and operating expenses.
Improved product saliency in high-margin emulsion categories to enhance the margin profile.
Statutory auditors Walker Chandiok & Co., LLP issued an unmodified opinion on FY26 financial results.
Strengthened business fundamentals despite persistent industry headwinds and volatile demand.
👀 What to Watch
Investors should view the shift to positive EBITDA as a major turnaround signal; focus on the sustainability of these margins and the company's ability to gain market share in the premium segment.
Halder Venture Revises Valuation Report for Preferential Issue of 7.93 Lakh Warrants
Halder Venture Limited has submitted a revised valuation report for its proposed preferential issue of 7,93,650 convertible warrants. The revision was triggered by observations from the NSE and BSE, which classified the company's equity shares as "frequently traded shares." This classification requires a valuation update in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The update ensures regulatory compliance for the capital raising process initiated on May 13, 2026.
Key Highlights
Proposed preferential issue involves 7,93,650 Convertible Warrants.
Revision follows NSE and BSE classification of shares as 'frequently traded'.
Valuation updated to comply with Chapter V of SEBI ICDR Regulations.
The company has uploaded the full revised valuation report to its official website for transparency.
👀 What to Watch
Investors should check the revised valuation report on the company's website to see if the warrant pricing has changed. Monitor for further updates on the final allotment and the intended use of the raised capital.
Shalby Q4 FY26 Consolidated PAT Surges 251% YoY to ₹185 Mn; EBITDA Up 43%
Shalby Limited reported a robust Q4 FY26 with consolidated revenue growing 9.4% YoY to ₹2,955 mn. The company achieved a significant 43.1% YoY growth in consolidated EBITDA to ₹374 mn, while PAT reached ₹185 mn, largely supported by the transition to a new tax regime. Operational metrics in the hospital business showed improvement with occupancy rising to 48% from 45% YoY, although surgery counts dipped by 6.7%. The MedTech segment continues to diversify the revenue stream, contributing 13.5% to the total quarterly turnover.
Key Highlights
Consolidated Q4 FY26 Revenue increased 9.4% YoY to ₹2,955 mn; Full-year FY26 revenue stood at ₹11,682 mn.
Consolidated EBITDA for Q4 FY26 rose 43.1% YoY to ₹374 mn, with margins improving to 12.7% from 9.7% YoY.
Hospital occupancy rate improved to 48% in Q4 FY26 vs 45% in Q4 FY25, while ARPOB grew 2.7% to ₹42,689.
Shalby MedTech (Implant business) generated ₹400.4 mn in revenue during the quarter, accounting for 13.55% of consolidated revenue.
Consolidated Net Debt as of March 31, 2026, stood at ₹4,462 mn with an annualized ROCE of 7.3%.
👀 What to Watch
Investors should focus on the company's ability to scale the high-margin MedTech business and the turnaround of the Shalby International (Delhi-NCR) unit, which is currently EBITDA negative. The core hospital business remains a steady cash generator with improving occupancy levels.
